For Immediate Release: August 25, 2016
Medpace Hosts Complimentary Webinar on Advanced Therapy Gene-Editing – Challenges and Future of CRISPR in Clinical Development
CINCINNATI, OH — (August 25, 2016) – Medpace experts Blythe Thomson, MD and Trevor Walker, DPhil, will engage in an interactive discussion on the topic of gene-editing technology and how it applies to human diseases.
WEBINAR: Gene Editing – Challenges and Future of CRISPR in Clinical Development
DATE: Thursday, September 29, 2016
TIME: 11am ET/ 8am PT
DURATION: 1 Hour
About the Webinar:
Gene editing technology is a rapidly evolving area of clinical and translational research that combines the potential of great advances with profound ethical challenges. Join Medpace medical and regulatory experts as they discuss the unique opportunity of this evolving technology as it applies to human diseases. Discussion will cover topics including:
- Basics of gene editing
- Potential applications
- Understanding clinical research challenges
- Regulatory considerations
- Ethical challenges and public perceptions
About the Presenters:
Blythe Thomson, MD – Senior Medical Director, Hematology & Oncology, Medpace
Dr. Blythe Thomson serves as a Medical Expert for hematology, oncology and hematopoietic cell transplantation studies at Medpace. She brings significant knowledge and experience to the topic of cellular therapy. She has provided medical leadership for cellular therapy trials during her professional career in both academia and industry.
Trevor Walker, DPhil – Associate Director, Regulatory Affairs, Medpace
Dr. Trevor Walker works collaboratively with the medical and operational teams to provide regulatory strategy and advice to ensure successful clinical development as well as leading specific regulatory activities. His global regulatory experience includes a variety of product types, therapeutic indications and geographic regions as well as a particular focus on advanced therapies. Trevor holds a DPhil in Pharmacology from Oxford University, and also has experience in manufacture of cellular therapies.
Medpace is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, and neuroscience. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people worldwide with operations in 35 countries.
For more information, please visit www.medpace.com